

Letters to the Editor

Aspergillosis Results Questioned

To the Editor:

I read with considerable interest and appreciation the report on "Nosocomial Aspergillosis in Patients with Leukemia Over a Twenty-Year Period" (1989; 10:299-305). After a thorough perusal of the data, it seems that there is a fairly major discrepancy between the data outlined in the section of the text describing aspergillosis in bone marrow transplant (BMT) recipients versus non-BMT recipients (1978-1983) and the data presented in Table 2.

The text in this section states "The greatest number of bone marrow transplants in leukemia patients took place in 1981 (18 patients), followed by 1982 (13 patients), 1983 (nine patients), 1978 (five patients), 1979 (four patients), and 1980 (four patients)." The text further states that during the years 1978 through 1983 "there were seven cases of invasive aspergillosis in BMT recipients-four cases in 1983, two cases in 1982 and one case in 1978." This gives us a total of seven cases in 53 patients.

Table 2 is labeled "Incidence of Aspergillosis in Bone Marrow Transplant Recipients and Non Bone Marrow Transplant Leukemia Patients at RPMI From 1978 to 1983." The denominator used for calculating the number of aspergillosis cases per 100 BMT recipients for each of the years should be the number of bone marrow recipients per year. If the data given in the text (quoted above) is used to construct Table 2 it should look like this:

	1978	1979	1980	1981	1982	1983	6-Year Incidence
All five types BMT	BMT	BMT	BMT	BMT	BMT	BMT	BMT
Number of cases/100 patients	20 (1/5)	0 (0/4)	0 (0/4)	0 (0/18)	15.4 (2/13)	44.4 (4/9)	13.2 (7 cases/53 patients)

It is not clear whether the authors have used the number of transplants as a denominator to determine the number of cases per 100 patients per year. If they have, the table should be labeled to reflect this. If this is the case, the information in the table is still discrepant with that which appears in the text. The part of the text when added up (quoted above) gives 53 patients receiving bone marrow transplants, whereas another portion of the text states there were 53 bone marrow transplants in 52 patients. In order to arrive at the figures derived by the authors in Table 2 the denominators used for 1978, 1982 and 1983 would have had to have been 6, 22 and 11 respectively. If we assume that these are the number of bone marrow transplants in these years and we consult the text to determine the number done in 1979, 1980 and 1981, it appears as though there were the following number of transplants done: 1978 (six), 1979 (four), 1980 (four), 1981 (18), 1982 (22), 1983 (11). This gives a total of 65 transplants, not 53 as stated in the text.

This paper represents a singularly fine contribution to the epidemiology of aspergillus infection in the bone marrow transplant patient. It is not at all difficult to imagine how the numbers in Table

2 may have become misarranged when one considers the enormous amount of data to be managed. Perhaps the authors could shed some light on the construction of Table 2 as it relates to the text?

Georgia P. Dash, MS, CIC
Philadelphia, PA

Coleman Rotstein, MD, Linda L. Klimowski, MS, MT (ASCP), CLS (NCA) and K. Michael Cummings, PhD, MPH were asked to respond to this letter.

We would like to clarify any misconceptions which Ms. Georgia P. Dash had about the article written by Klimowski, et al.' There were indeed 53 bone marrow transplants performed on 52 patients with leukemia. One patient who had chronic myelogenous leukemia was transplanted twice. The distribution of the patients' underlying diseases was as outlined in the text. The number of transplants performed between 1978 and 1983 was also correctly stated in the text: 1978 (five transplants), 1979 (four transplants), 1980 (four transplants), 1981 (18 transplants), 1982 (13 transplants) and 1983 (nine transplants), for a total of 53 bone marrow transplants. Seven cases of invasive aspergillosis occurred in the bone marrow transplant recip-

ients: four cases in 1983, two cases in 1982 and one case in 1978. Thus, there were a total of seven cases among the 53 transplant recipients.

The data presented in Table 2 are in fact correct. Any apparent discrepancy can be explained on the basis that care of the transplant patients often overlapped from one year to the next and patients were often admitted more than once in the six-year period, therefore contributing days at risk for two or more years. Thus, more patients than were actually transplanted in a particular year were included in the data analysis. This inflated the total number of patients at risk for that particular year. Therefore, the denominator figure representing the annual

number of patients at risk would be larger than one might expect. Indeed this lowered the incidence rate.

We hope this explanation clarifies any misconceptions or doubts which existed about the data. The authors greatly appreciate Ms. Dash's careful perusal of the data.

Coleman Rotstein, M.D.
Linda L. Klimowski, MS, AT(ASCP),
CLS(NCA)
K. Michael Cummings, PhD, MPH
Hamilton, Ontario, Canada


REFERENCE

1. Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in patients with leukemia over a twenty-year period. *Infect Control Hosp Epidemiol.* 1989; 10:299-305.

Letters to the Editor should be addressed to INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY Editorial Offices, C41 General Hospital, University of Iowa Hospitals and Clinics, Iowa City, IA 52242. All letters must be typed, double spaced and may not exceed four pages nor include more than one figure or table. The editors reserve the right to edit for purposes of clarity or brevity.

NEW **Engerix-B[®]**
Hepatitis B Vaccine
(Recombinant)

**Protection from
Hepatitis B
When You Need It**



Please see
brief summary of
prescribing information
at the end of this ad.

NEW **Engerix-B®**
Hepatitis B Vaccine
(Recombinant)

**New 0, 1, 2 Month Dosing Regimen
for Certain Populations***

New 20 mcg Recombinant Dose

	Engerix-B*	Recombivax HB*†
Adult dose (mcg)	20	10
Standard dosing regimen (0, 1 and 6 months)	Yes	Yes
New 0, 1, 2 month dosing regimen** for certain populations	Yes	No
Published efficacy data: Neonates born of infected mothers ¹	Yes	Yes
VACTRAC™—computer software for vaccination tracking and compliance	Yes	No
Bar-coded, unit-dose vials	Yes	No
Lowest cost per dose ²	Yes	No

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers.

†Hepatitis B Vaccine (Recombinant), MSD.

**When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

Lowest Cost Per Dose


Extensively Tested and Well Tolerated*

- State-of-the-art recombinant technology—
6 million doses distributed in over 80 countries

Switch to 'Engerix-B'

- Can be used to complete a course of vaccination initiated
with another hepatitis B vaccine

NEW **Engerix-B[®]**
Hepatitis B Vaccine
(Recombinant)



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
Smith Kline & French Laboratories
Philadelphia, PA 19101

*Please see brief summary of prescribing information at the end of this ad for a complete listing of adverse reactions, contraindications, warnings and precautions.

© SmithKline Beckman Corporation, 1989

NEW **Engerix-B®** Hepatitis B Vaccine (Recombinant)



Protection from Hepatitis B When You Need It

- 0, 1, 2 Month Dosing Regimen*
- 20 mcg Recombinant Dose
- Lowest Cost per Dose²

Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
Smith Kline & French Laboratories
Philadelphia, PA 19101

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers.

Engerix-B® Hepatitis B Vaccine (Recombinant)

See complete **prescribing information** in **SK&F** literature or **PDR**. The following is a brief **summary**.

INDICATIONS AND USAGE: 'Engerix B' is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus.

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

WARNINGS: Do not give additional injections to patients experiencing hypersensitivity after an 'Engerix B' injection. (See **CONTRAINDICATIONS**)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

PRECAUTIONS: General: As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with 'Engerix B'. It is also not known whether 'Engerix B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give 'Engerix B' to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether 'Engerix B' is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving 'Engerix B' to a nursing woman.

Pediatric Use: 'Engerix B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine.

ADVERSE REACTIONS: 'Engerix B' is generally well tolerated. During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix B' and plasma-dewaxed vaccines. In 36 clinical studies a total of 13,495 doses of 'Engerix B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers and healthy neonates. All subjects were monitored for 4 days post administration. Frequency of adverse experiences tended to decrease with successive doses of 'Engerix B'. Using a symptom checklist, the most frequently reported adverse reactions were injection site soreness (22%), and fatigue* (14%). Other reactions are listed below.

Incidence 1% to 10% of Injections: Induration; erythema; swelling; fever (> 37.5°C); headache; dizziness.

*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

Incidence < 1% of Injections: Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain; cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia/myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of 'Engerix B' outside the United States. Those listed below are to serve as alerting information to physicians. Anaphylaxis; erythema multiforme including Stevens Johnson syndrome; angioedema; arthritis; tachycardia; palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia; paresthesia; Guillain Barre syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

Potential Adverse Experiences In addition certain other adverse experiences not observed with 'Engerix B' have been reported with Heptavax-B*† and/or Recombivax HB®‡. Those listed below are to serve as alerting information to physicians. Optic neuritis.

HOW SUPPLIED: 20 mcg/mL in Single Dose Vials in packages of 1, 10 and 25 vials.

NDC 0007-3860-01 (package of 1)
NDC 0007-3860-11 (package of 10)
NDC 0007-3860-16 (package of 25)

10 mcg/0.5 mL in Single Dose Vials in packages of 1 vial
NDC 0007-3859-01 (package of 1)

† plasma-dewaxed, Hepatitis B Vaccine, MSD
‡ yeast dewaxed, Hepatitis B Vaccine, MSD

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium
Distributed by **Smith Kline & French Laboratories**
Division of SmithKline Beckman Corp., Philadelphia, PA 19101

Date of issuance Aug 1989

BRS-EB L6

EB901A

© SmithKline Beckman Corporation, 1989

Engerix B is a registered trademark of SmithKline Beckman Corporation

1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281. 2. Based on published prices, August 1989.